Riddhi Siddhi Gluco Biols is a listed company. Filings by its managers are published through SEBI (PIT + SAST). Over the twelve months to 26 October 2026, 3 filings were filed, from 3 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Insider buying of Riddhi Siddhi Gluco Biols has been absent for the past year. The median gap between trade and publication is zero days: most filings appear on the same day. That lag is the time during which only the insider knows about the trade.
With 3 filings in twelve months, the company is quieter than the median of 4 filings across the 1,985 companies we follow on the same exchange.
This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
3 of 3 declarations
Riddhi Siddhi Gluco Biols is a company listed on XBOM, specializing in the production of glucose-based products and other derivatives. It focuses on innovation and sustainability in its manufacturing processes.